Written by The US Genetic Testing Market is becoming an increasingly important part of precision healthcare in the United States. Genetic information can support disease-risk assessment, diagnosis, treatment selection, and preventive care. Growing public awareness of hereditary conditions, combined with technological progress, is encouraging broader adoption of genetic testing across healthcare settings.
Whole exome sequencing represents a leading testing type because it provides extensive information about protein-coding regions of the genome. Panel testing and whole genome sequencing also play important roles, while non-invasive prenatal testing is emerging as a rapidly growing area. Continued improvements in sequencing technologies are helping make complex genetic analysis more efficient and accessible.
Clinical laboratories account for the largest end-user share because of their established infrastructure and ability to perform high volumes of specialized testing. Hospitals are also increasing their investment in genetic diagnostic services as genomic information becomes more relevant to routine clinical care. Research institutions and homecare settings provide additional opportunities for specialized and personalized testing.
The market’s competitive landscape includes major companies such as Illumina, Thermo Fisher Scientific, Roche, Myriad Genetics, 23andMe, Invitae, and Fulgent Genetics. Companies are focusing on sequencing innovation, diagnostic solutions, partnerships, and personalized healthcare applications. As genetic testing becomes more integrated into healthcare systems, competition and innovation are expected to intensify.
Gain valuable insights through comprehensive industry analysis:
Oligonucleotide Synthesis Market Outlook